Tradestie Institutional Equity Comparison Engine

RGNX vs DMAC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DMAC Overall Edge

DMAC Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DiaMedica Therapeutics Inc. Common Stock (DMAC) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while RGNX counters with relative strength in Valuation. Fundamentally, RGNX trades at N/M Forward P/E with -120.4% operating margin (-69.2% YoY revenue) versus DMAC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against DMAC sits in SURGE (14th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner RGNX
RGNX N/M vs DMAC N/M Fwd P/E
Growth & Margin Winner DMAC
Op Margin -120.4% vs 0.0% ยท YoY -69.2% vs +0.0%
Momentum & Technical Winner DMAC
1Y -35.8% vs +55.3% ยท 52W Pos 19% vs 55%
Options & Structure Winner DMAC
BREAKDOWN (52nd %ile IV) vs SURGE (14th %ile IV)
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
1M Return +7.87%
1Y Return -35.82%
Forward P/E N/M
Unified AI Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
DMAC NASDAQ
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
1M Return +11.16%
1Y Return +55.26%
Forward P/E N/M
Unified AI Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RGNX -35.82% DMAC +55.26% Spread: +91.08 pp (DMAC Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RGNX Revenue DMAC Revenue RGNX Op. Margin DMAC Op. Margin Margin Edge
FY2018 $220M $0M 40.3% -1352.2% RGNX
FY2019 $40M N/A -422.9% N/A RGNX
FY2020 $150M N/A -77.1% N/A RGNX
FY2021 $470M N/A 34.0% N/A RGNX
FY2022 $110M N/A -233.2% N/A RGNX
FY2023 $90M N/A -297.1% N/A RGNX
FY2024 $80M N/A -280.0% N/A RGNX
FY2025 $170M N/A -94.6% N/A RGNX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RGNX (2) vs DMAC (5)
Institutional Metric RGNX DMAC Criterion Row Winner
Market Capitalization Scale $500.9M $503.1M Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -69.2% +0.0% Higher Growth DMAC
Operating Margin (TTM) Profitability -120.4% 0.0% Higher Margin DMAC
Net Profit Margin Profitability -113.9% 0.0% Higher Margin DMAC
Return on Equity (ROE) Capital Efficiency -113.2% -114.6% Higher ROE RGNX
52-Week Range Position Momentum 19% ($5โ€“$16) 55% ($5โ€“$11) Stronger Trend DMAC
Beta / 30D Volatility Risk Regime 1.81ฮฒ ยท 76% Vol 1.74ฮฒ ยท 98% Vol Lower Realized Risk RGNX
Unified Institutional Score Composite Signal 45.3 / 100 (HOLD) 46.3 / 100 (HOLD) Higher Composite DMAC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RGNX vs DMAC Buy Guide
RGNX BREAKDOWN
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
DMAC SURGE
8d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 14th %ile
IV Regime Compressed (<25th %ile)
Live DMAC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RGNX nor DMAC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.